We are passionate about harnessing the power of modern technology to innovate the biotechnological landscape and develop real world solutions for the benefit of society. We focus on leveraging the power of data science, AI, and automation to discover and understand protein-protein interactions with a particular focus on binders, such as antibodies, nanobodies, and minibinders. Specifically, we are interested in (1) building de novo peptide sequencing solutions such as InstaNovo to identify key protein targets, as well as (2) the discovery, AI-design, and engineering of binding proteins. Importantly, this not only allows us to pursue fundamental questions, such as unravelling the core rule set that dictates binder-target interactions and poly- vs mono-specificity, but also translational endeavours, such as discovering cost-effective reagents, diagnostics, and therapeutics within a plethora of areas including toxins, cancer, viral infections, allergy, and bioindustrials.